skip to Global Navigation Bar skip to main content

homeHome > Global Business > Licensing Opportunities

 Licensing Opportunities

* Easyef : Highlights
What is Easyef ? (Epidermal Growth Factor)
  • • Epidermal growth factors to induce skin cell and keratocyte regeneration.
  • • Effective in curing keratohelcosis, corneal disorders, wounds, diabetic ulcer, bedsore, etc
    Daewoong succeeded in mass-producing Easyef equivalent to the human one and medicalized it first in the world.
Product Profile
  • • Ingredient: Recombinant human Easyef (host cell: Escherichia coli JM101, vector: pTE105)
  • • Indication: Diabetic foot ulcer , mucositis (PIII)
  • • Usage: Mix main ingredient and solvent and apply a proper dose of the
    mixture to the affected part twice a day in the morning and evening
  • • Characteristics: Colorless, transparent liquid
  • • Packaging Unit: 10ml (50㎍/㎖)
  • • Storage: Cold storage (2~8℃)
* Easyef ointment: Highlights
Product Profile
  • • Ingredient
    1) Active ingredient: 1g contains Recombinant Human Epidermal Growth Factor 1ug
    (host cell: Escherichia coli JM101, vector: pTE105)
    2) preservative : Isopropyl p-Hydroxybenzoate (KP) 1.5mg
  • • Indication: wound, topical adjuvant therapy of skin ulcer
  • • Usage: several times per day apply for wound
  • • Contents: ointment containing colorless or odorless in tube
  • • Development status: already marketed in Korea
  • • Contain no steroid and antibiotics
  • • Established efficacy and safety by clinical trial
  • • New concept of wound treatment which contain Easyef (epidermal growth factor)
Product Name & Active Ingredients Indications & Usage Features Package
Ursa soft cap.
Ursodeoxycholic acid -------- 50mg
Thiamin HNO3 -------------- 10mg
Riboflavin ---------------------- 5mg
For the improvement of chronic hepatic disease;.Systemic lassitude, body fatigue, dyspepsia and anorexia caused by liver function impairment • DAEWOONG's top brand for a decade.
• Tonic & nutrition; Relief from fatigue& hangover,Improvement of hepatic function
• The combined therapy for hepatic & biliary disease
10,60,100,120 Cap/Box
Ursa complex soft cap.
Dry ginseng ext.----------------50mg
Ursodeoxycholic acid----------25mg
Thiamin Nitrate-----------------10mg
Ursa 100mg tab.
Ursodesoxycholic acid ---- 100mg
Improvement of liver function of chronic hepatic diseases, hepatic disease associated with biliation failure, diseases in biliary tract system; Hyperlipemia, cholelithiasis, dyspepsia of inflammatory small intestinal diseases and sequela of small intestinal removal.Primary Biliary Cirrhosis • Excellent effect on Hepatic and biliary diseases
• Rapidly excreting toxic metabolite from the liver & biliary tract
• Safe drug approved by FDA (cholelithotriptic, prophylaxis of chlolelith, PBC remedy)
100 Tab/Btl.10,30,60,100 Tab/Box
.50 Cap/PTP
Ursa 200mg tab.
Ursodesoxycholic acid ---- 200m
Ursa 300mg tab.
Ursodeoxycholic acid ------- 300mg
Ursa 100mg soft cap.
Ursodeoxycholic acid ------- 100mg
Ursa 250mg cap.
Ursodeoxycholic acid ------- 250mg
Product Profile
  • • Ingredient: Ranitidine ? HCI 84mg (as ranitidine 75mg)+ Bismuth subcitrate 100mg + Sucralfate 300mg
  • • Indication: Gastric & duodenal ulcer, gastritis, Zollinger-Ellison syndrome,reflux esophagitis, preanesthetic use, postoperative ulcer, gastric & duodenal ulcers due to NSAIDs
  • • Mechanism: synergic action of three components helps higher treatment rate of GI ulcer
  • • Usage: regardless of meal. 2 tab, twice a day, in the morning and at bedtime
  • • Formulation: double-core tablet
  • • Development status: already marketed in Korea and Vietnam
  • • Double-core tablet :less component's drug interaction
  • • Synergic action of three components helps higher treatment rate of GI ulcer
  • • 3 action : protects mucosa, prohibits secretion of gastric acid and suppresses H. pylori
* DWP431: Recombinant human bone morphogenetic protein-2
Indication: Bone regeneratio
  • • Dental & Orthopaedic applications
  • • $1.5B in US markets :
Candidate Profile
  • • 26 kDa homodimer protein
  • • Promotes differentiation from mesenchymal stem cells to osteocytes
  • • Developed as medical device composed with
       - Artificial bone carrier
       - BMP-2
Development Status
  • • 2010, 10 PIII for alveolar augmentation
  • • 2011, 02 PIII for spinal fusion in chronic disc degeneracy
* DWP09031: Novel Alzheimer Treatment
Indication: Alzheimer's Disease
  • • Most common form of dementia and causes impaired cognitive function
  • • No effective therapeutic solution
  • • $7.9B in 7 major markets (2010) & 25% CAGR
Candidate Profile
  • • A novel small molecule Aß aggregation inhibitor
  • • Highly stable solid
  • • No issue in the bulk campaign up to 20 kg
  • • Solid patent profiles (KR10-2006-0097388, PCT/KR07/004833)
Development Status
  • • Preclinical
* DWP05195: Novel Pain Treatment
Indication: Neuropathic Pain
  • • Caused by primary lesion or dysfunction of the nervous system
  • • No effective pharmacological solution
  • • $2.3B in 7 major markets ($6.3B in 2017)
Candidate Profile
  • • A novel small molecule TRPV1 antagonist
  • • Highly stable (3yrs in RT)
  • • Simple synthetic steps
  • • Solid patent profiles (WO2006/080821, WO2008/007900)
Development Status
  • • Clinical PI completed successfull
Product Profile
  • • Ingredient: Tamsulosin HCl 0.2mg + Finasteride 5mg
  • • Indication: Benign Prostatic Hyperplasia
  • • Mechanism: To relax the smooth muscle of prostate, To reduce the size of prostate
  • • Usage: QD (Once a day)
  • • Formulation: Capsule
  • • Development status: Phase III in Korea, PIII will be started in China
Active Ingredients
  • Leuprolide acetate -- 3.75mg
Indications & Usage
  • Prostatic cancer, Endometriosis, Premenopausal breast cancer, Uterine leiomyomata (Fibroids), Central precocious puberty
Dosage & Administration
  • • Usual recommended dose is 3.75mg administered as a single subcutaneous injection every month.
  • • Synthetic analog of gonadotropin releasing hormone (GnRH)
  • • Suppress the hormone to castrate or post-menopausal levels
  • • Gelatin free formulation
  • 1Vial/1prefilled syringe
Active Ingredients
  • Each prefilled syringe (0.5mL) contains Recombinant human erythropoietin …2,000, 3,000, 4,000, 5,000, 6,000, 8,000, 10,000IU
Indications & Usage
  • Anemia of chronic renal failure patients
    1) Secondary anemia
    2) Anemia required blood transfusion
Dosage & Administration
  • • initial dose: 50units/kg for 1-2 minutes three times a week IV or SC The dose can be increased, if necessary, by 25 units/kg in 4-week period. If hemoglobin is increased more than 2 g/dl at a dose of 50 units/kg, the frequency should be reduced to two times a week.
  • • To correct the anemia, the target concentration of hemoglobin is 10 g/ dl (30% as hematocrit). When the anemia is corrected, Eposis is given as a maintenance dose of 25 - 50 units/kg two or three times a week
  • • Recombinant human erythropeietin produced by Daewoongs topnotched genetic engineering technology
  • • Convenient, ready to use format, prefilled syringe type
  • • 6 Syringes/Box
Active Ingredients
  • Somatropin Lyophilized powder (16 IU, 4 IU) Somatropin Liquid cartridge with pen-type syringe (22 IU)
Indications & Usage
  • Growth Hormone Deficiency in adult
Dosage & Administration
  • • Adult Growth Hormone Deficiency (GHD) The recommended dosage at the start of therapy is 0.125IU (0.04mg) /kg/week given as a daily subcutaneous injection (6~7 divided dose). The dose may be increased gradually according to individual patient requirements to a maximum of 0.25IU (0.08mg)/kg/week. Clinical response, side effects, and determination of age-and gender-adjusted serum insulin-like growth factor(IGF-1) levels may be used as guidance in dose titration. Minimum effective dose should be used. The dosage of somatropin should be decreased in cases of persistent edema or severe paresthesia, in order to avoid the development of carpal tunnel syndrome
  • • 4, 16IU - Lyophilized powder: 1 set (Main drug part 1 via & Diluent 1 vial)
  • • 22IU - Liquid cartridge with pen-type syringe
Indications & Usage
  • Acute wounds, subacute wounds, chronic wounds, post operative wounds
  • • Negative Pressure Wound Therapy
  • • A mechanical wound care treatment that uses controlled negative pressure to assist and accelerate wound healing
  • • Remove excess fluid and edema
  • • Maintains a moist wound environment
  • • Encourages wound contraction
  • small(10x7.5x3cm)
Active Ingredients
  • Meropenem ----------- 500mg
Indications & Usage
  • Sepsis, cellulitis, lymphadenitis, perianal abscess, osteomyelitis, arthritis, wound infection,pneumonia, peritonsillar abscess, bronchiectasis, secondary infection of chronic respiratory disease, lung abscess, pyothorax, pyelonephritis, complicated cystitis, cholecystitis, cholangitis, liver abscess, peritonitis, adnexitis, intrauterine infection, pelvic dead space infection, pelvic cellulitis, otitis media, paranasal sinusitis, bacterial meningitis, suspected infection in patients with leucopenia, cystic fibrosis
  • • Beta-lactam antibiotic agent
  • 10Vial/Box
Active Ingredients
  • • Active ingredient : Iopromide
  • • Excipients : tromethamine, edetate calcium disodium
  • • Iopromide API synthesized from a patented procedure to ensure the quality and safety of the drug.
  • • First generic version of Ultravist® (Bayer Healthcare Pharma).
  • • APIs‘ & Product’s quality satisfies both USP 32 and EP6.5
Active Ingredients
  • • Clostridium botulinum Toxin Type A----------100 Units
  • • Stabilizing agent: Human serum albumin----0.5 mg
  • • Isotonic agent: Sodium Chloride-------------0.9mg
Indications & Usage
  • • Temporary improvement of forehead lines associated with corrugator and/or procerus muscle activity in adult patients between 20 to 65 years old
  • • Upper limb spasticity after stroke in adult patients above 18 years old
  • • 50Units, 100Units, 200Units